Qiagen's FDA Clearance: A Diagnostic Market Shift or Just a Glimmer of Hope?
The recent FDA clearance of Qiagen's QIAstat Dx BCID GPF Plus AMR Panel marks a significant milestone for the company, but its implications are far from straightforward.
On one hand, it represents a long awaited entry into the US bloodstream infection testing market, with the potential to tap into higher margin hospital diagnostic channels.